Expertise in
9
conditions

Dr. Marjory Charlot

Oncology
Office
830 Harrison Ave Ste 3200, 
Boston, MA 
Expertise in
9
conditions
Office
830 Harrison Ave Ste 3200, 
Boston, MA 

Overview

Marjory Charlot is an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Charlot is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

She is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 9 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MA

Hospital Affiliations

Unc Hospitals

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Office
830 Harrison Ave Ste 3200, Boston, MA 02118
Other Locations
UNC Hospitals Pulmonary Function Lab
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 8 Less Clinical Trials

41 Total Publications

Enrollment Patterns and Site-Level Predictors of Black Participant Recruitment to a Multisite Randomized Cancer Clinical Trial.
Enrollment Patterns and Site-Level Predictors of Black Participant Recruitment to a Multisite Randomized Cancer Clinical Trial.
Journal: JCO oncology advances
Published: January 26, 2026
Similar Doctors
Expertise in
27
conditions
Dr. Jeremy Abramson
Oncology
Expertise in
27
conditions
Dr. Jeremy Abramson
Oncology
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (617.7 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Abramson is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Abramson is highly rated in 27 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
20
conditions
Dr. Matthew Davids
Oncology
Expertise in
20
conditions
Dr. Matthew Davids
Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (615.0 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Davids is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Davids is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology
Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (615.0 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jacobsen is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Jacobsen is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Marjory Charlot

How do I make an appointment with Dr. Marjory Charlot?

You can book an appointment with Dr. Marjory Charlot by calling their office at 617-638-6428. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marjory Charlot a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marjory Charlot is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marjory Charlot specialize in?

While Dr. Marjory Charlot is a Oncology, they have specific expertise in Lung Cancer, ALK-Positive Non-Small Cell Lung Cancer, and Squamous Cell Lung Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Marjory Charlot participate in research or clinical trials?

Yes. Dr. Marjory Charlot has published 41 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Marjory Charlot's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marjory Charlot accept my insurance?

Dr. Marjory Charlot accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 617-638-6428 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Charlot's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile